Correspondence  |   August 2017
Is the PeriOperative ISchemic Evaluation-2 Trial Equipoised?
Author Notes
  • Hôtel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon (G.S.). ghassan.sleilaty@usj.edu.lb
  • (Accepted for publication May 8, 2017.)
    (Accepted for publication May 8, 2017.)×
Article Information
Correspondence
Correspondence   |   August 2017
Is the PeriOperative ISchemic Evaluation-2 Trial Equipoised?
Anesthesiology 8 2017, Vol.127, 399-400. doi:10.1097/ALN.0000000000001727
Anesthesiology 8 2017, Vol.127, 399-400. doi:10.1097/ALN.0000000000001727
We read with interest the article by Eikelboom et al.1  reporting the results of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial regarding postoperative incidence of venous thromboembolism (VTE).
We had several concerns:
In conclusion, POISE-2 was underpowered to assess the ability of aspirin to prevent VTE. From the authors’ perspective, this major weakness was to be imputed to the low VTE rate. From ours, it stems from the insufficient sample size, for VTE rate was known a priori. Increasing sample size by pooling POISE-2 with PEP and APTC cannot fix this shortcoming due to different patient populations.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large